The endocannabinoid system shows promise for bladder pain but faces challenges in clinical translation | Research

The takeaway

A review of endocannabinoids for bladder pain found strong preclinical evidence that boosting endocannabinoid levels can prevent pain development, but translating this to clinical treatments remains difficult.

Read this if you have bladder pain and are interested in emerging treatment approaches beyond opioids.

Endocannabinoid enzyme inhibitors prevented pain development in animal models

What the researchers found

Bladder-related pain is one of the most common forms of visceral pain, and opioids remain a primary treatment despite their well-known side effects. Researchers reviewed the potential of the endocannabinoid system as an alternative therapeutic target.

Animal experiments have shown that inhibiting the enzymes that break down the endocannabinoids anandamide (AEA) and 2-AG can prevent the development of both visceral and somatic pain. By blocking fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), endocannabinoid levels rise naturally, producing analgesic effects without the psychoactive properties of exogenous THC.

However, several challenges limit clinical translation. Anandamide also activates TRPV1 pain channels, which could paradoxically increase pain at certain concentrations. Cyclooxygenase (COX) enzymes also metabolize endocannabinoids, complicating the pharmacology. Dual inhibitors targeting FAAH plus TRPV1, or FAAH plus COX, are being developed to address these challenges. Local application within the bladder could potentially deliver effects with fewer systemic side effects.

Why it matters

Bladder pain conditions like interstitial cystitis affect millions of people and are notoriously difficult to treat. The endocannabinoid system offers a mechanistically distinct approach from opioids, potentially providing pain relief without the addiction risk and side effects that make long-term opioid use problematic for chronic bladder conditions.

The numbers in context

Two primary endocannabinoids reviewed: anandamide (AEA) and 2-AG. Two primary degrading enzymes: FAAH (degrades AEA) and MAGL (degrades 2-AG). Dual inhibitors under development: FAAH + TRPV1 blockers, FAAH + COX inhibitors. Local bladder application proposed but not yet explored.

How the study worked

This was a narrative review of the endocannabinoid system as a therapeutic target for bladder pain, examining preclinical evidence for endocannabinoid-modulating approaches, pharmacological challenges, and emerging dual-inhibitor compounds.

What this study cannot tell us

Most evidence comes from animal models, and clinical translation of FAAH and MAGL inhibitors has been disappointing in some cases. The complex pharmacology involving multiple enzymes and receptors makes drug development challenging. The review is focused on bladder pain specifically, and findings may not apply to other pain conditions. No human clinical data on endocannabinoid modulation for bladder pain were available.

How to read the evidence

This is a narrative review of predominantly preclinical evidence, providing moderate-level guidance on a promising but not yet clinically validated approach.

When this study was published

Published in 2018. Endocannabinoid-based pain research has continued, though clinical translation remains challenging.

The bigger picture

This review represents part of a broader effort to harness the endocannabinoid system for pain management without using cannabis or THC directly. By boosting the body's own endocannabinoids rather than introducing exogenous cannabinoids, this approach could potentially avoid psychoactive effects while still providing pain relief through cannabinoid receptor activation.

Questions still open

Can local delivery of endocannabinoid-modulating drugs to the bladder achieve therapeutic concentrations without systemic effects? Will dual inhibitors overcome the challenges that have limited single-target approaches? How does the endocannabinoid system interact with current bladder pain treatments?

Common questions

Can cannabis treat bladder pain?

This review did not examine cannabis directly but rather the potential of boosting the body's own endocannabinoids for bladder pain. Animal studies show promise, but human clinical data are lacking. The approach differs from using cannabis in that it enhances natural endocannabinoid signaling rather than introducing plant-derived cannabinoids.

Why not just use opioids for bladder pain?

Opioids remain a mainstay for bladder pain management, but their side effects, including sedation, constipation, and addiction risk, significantly diminish quality of life. Endocannabinoid-based approaches could potentially provide pain relief without these side effects, though they are still in preclinical development.

Read the original research

Potential of Endocannabinoids to Control Bladder Pain.

Frontiers in systems neuroscience, 12, 17

View on PubMed ↗Publisher’s paper ↗

Citation

Bjorling, Dale E; Wang, Zun-Yi. (2018). Potential of Endocannabinoids to Control Bladder Pain.. Frontiers in systems neuroscience, 12, 17. https://doi.org/10.3389/fnsys.2018.00017